WHO hails 'triumph' as Merck's Ebola vaccine gets European green light

2020-02-24 16:40:15    阅读:358800

LONDON (Reuters) - The world’s first Ebola vaccine was recommended for approval by European drugs regulators on Fri

day in a move hailed by the World Health Organization (WHO) as a “triumph for public health” that would save many lives. FILE PHOTO: The Merck logo is seen

at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermidThe vaccine, developed by U.S. drugmaker Merck & Co, is already being used under emergency guidelines to try to protect people against the spread of a deadly Ebola outbreak in Democratic

Republic of Congo. It protects against the Zaire strain of the Ebola virus - the one that most commonly causes outbreaks. The shot is also being reviewed under a fast-track system by regulators in the United States, with a deci

sion expected in the first quarter of next year. “This vaccine has already saved many lives in the current Ebola outbreak, and the decision by European regulators will help it to eventually save many more,” the WHO’

s director-general Tedros Adhanom Ghebreyesus said in a statement. The Congo Ebola outbreak has killed more than 2,100 people since the middle of last year. It is the second-largest Ebola outbr

eak in history, after a 2013-16 epidemic in West Africa that killed more than 11,300. The Merck vaccine, which the company has now brand-named Ervebo, is likely to get a full marketing license from the European Commission in a few weeks. Roger Perlmutter, president of Merck Research Laboratories, said the company’s priority now was to ge

t regulatory

approval of its Ervebo manufacturing site in German

y so that lic

ensed supply of the vaccine “can be used to support global public health preparedness”. Merck’s vaccin2020年第十三期玄机图 e is being used in Congo in a so-called “ring vaccination” approach, in which people who may have been in contact with someone newly infected with Ebola are traced and offered the sh

ot to protect them. Charlie Weller, head of vaccines at the Wellcome Trust global heath charity said the Merck s

hot had already saved “countless lives” in the country. “Having this vaccine available under research conditions has been key in preventing the ongoing outbreak in the DRC spiraling into a r

epeat of the 2014-16 epidemic, w

here 11,000 people died,” she told Reuters. Health authorities in Kinshasa said last week they planned to introduce an experimental second Ebola vaccine, developed by drugmaker Johnson & Johnson, in the country’s eastern provinces in November. The Ebola virus causes hemorrhagic fever and spreads from person to person through direct contact with body fluids. It kills around hal

f of those it infects. There are currently no licensed treatments for the deadly infection, but scientists said in August they were a step closer to being able to cure it after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo.

正规公司,值得信赖

工商注册备案,安全可靠!

安全保障,持证上岗

三证齐全(身份证,健康证,育婴师证)疾病排查,身份联网确认

异地服务,更贴心

专注母婴护理,你在哪,我们的服务就在哪里